Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab for Steroid Refractory Acute GVHD
NCT00578591Phase 2Withdrawn
- Sponsor
- Baylor College of Medicine
- Start
- Jun 2007
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in Acute Graft-Versus-Host Disease (aGvHD), sponsored by Baylor College of Medicine. Planned start Jun 2007; status: withdrawn.
02
Drugs
rituximab
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT00578591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00578591.